Strata Acquires National Heart & Lung Transplant Program, Bolstering Organ Recovery Platform
SRTA sits 57% above its 52-week low of $3.57.
Summary
Strata Critical Medical has acquired a Heart and Lung Transplant National Recovery Program, significantly expanding its national organ recovery platform. This strategic acquisition follows the company's recent purchases of Ohio Valley Perfusion Associates and Louisville Perfusion Services, demonstrating a clear pattern of aggressive growth. The move builds on Strata's strong Q1 2026 financial results, which included an 87.4% year-over-year revenue increase. This acquisition solidifies Strata's position in a critical medical niche.
At the time of this announcement, SRTA was trading at $5.61 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $482M. The 52-week trading range was $3.57 to $6.50. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.